Drug intelligence / Profile preview

ND088

Development stage: Preclinical
Lead developer: Numab Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ND088 is a potential first-in-class multispecific antibody being developed by Numab Therapeutics for the treatment of asthma and other respiratory diseases. Engineered using Numab's proprietary λ-Cap™ and MATCH™ technology platforms, ND088 is designed to simultaneously neutralize three complementary disease-driving pathways that contribute to bronchial hyperresponsiveness. This multispecific biologic modality aims to provide enhanced therapeutic efficacy by addressing the complex, multi-factorial nature of respiratory disease pathophysiology while maintaining tailored pharmacokinetic properties.

Beyond the preview

Go deeper on ND088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND088.

Explore the full profile